Carbapenems versus beta-lactam/beta-lactamase inhibitors to treat ESBL-producing Enterobacteriaceae infections

Med Mal Infect. 2020 Jun;50(4):313-315. doi: 10.1016/j.medmal.2019.09.010. Epub 2019 Oct 14.
No abstract available

Keywords: BLSE; Beta-lactam/beta-lactamase inhibitors; Bêta-lactamines-inhibiteurs de bêta-lactamases; Carbapenems; Carbapénèmes; ESBL.

Publication types

  • Editorial

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use*
  • Cephalosporin Resistance
  • Cohort Studies
  • Drug Resistance, Multiple, Bacterial
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae / genetics
  • Enterobacteriaceae Infections / drug therapy
  • Humans
  • Meta-Analysis as Topic
  • Multicenter Studies as Topic
  • Observational Studies as Topic
  • Piperacillin, Tazobactam Drug Combination / pharmacology
  • Piperacillin, Tazobactam Drug Combination / therapeutic use*
  • Randomized Controlled Trials as Topic
  • beta-Lactam Resistance
  • beta-Lactamase Inhibitors / therapeutic use*
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactamase Inhibitors
  • Piperacillin, Tazobactam Drug Combination
  • beta-Lactamases